Switch theme
Sign up to access all valuation multiples
Hammadi Holding is engaged in the activities of wholesale and retail trading of medical equipment, pharmaceutical and cosmetic products, establishing, managing, and operating hospitals and medical centers, wholesale and retail trading of food and beverages, purchasing and rentals of lands for construction buildings and investing, initiating commercial centers, operating and maintaining them. The operating segment of the company are Medical Services and Pharmaceuticals Products segment. It generates maximum revenue from the Medical Services segment. The Medical Services segment includes fees for inpatient and outpatient services.
2004
n/a
LTM Revenue $320M
LTM EBITDA $116M
$1.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Hammadi has a last 12-month revenue (LTM) of $320M and a last 12-month EBITDA of $116M.
In the most recent fiscal year, Hammadi achieved revenue of $308M and an EBITDA of $127M.
Hammadi expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Hammadi valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $320M | XXX | $308M | XXX | XXX | XXX |
| Gross Profit | $106M | XXX | $102M | XXX | XXX | XXX |
| Gross Margin | 33% | XXX | 33% | XXX | XXX | XXX |
| EBITDA | $116M | XXX | $127M | XXX | XXX | XXX |
| EBITDA Margin | 36% | XXX | 41% | XXX | XXX | XXX |
| EBIT | $85.5M | XXX | $77.3M | XXX | XXX | XXX |
| EBIT Margin | 27% | XXX | 25% | XXX | XXX | XXX |
| Net Profit | $87.4M | XXX | $90.4M | XXX | XXX | XXX |
| Net Margin | 27% | XXX | 29% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Hammadi's stock price is SAR 37 (or $10).
Hammadi has current market cap of SAR 6.0B (or $1.6B), and EV of SAR 6.0B (or $1.6B).
See Hammadi trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.6B | $1.6B | XXX | XXX | XXX | XXX | $0.55 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Hammadi has market cap of $1.6B and EV of $1.6B.
Hammadi's trades at 5.2x EV/Revenue multiple, and 12.6x EV/EBITDA.
Equity research analysts estimate Hammadi's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Hammadi has a P/E ratio of 18.3x.
See valuation multiples for Hammadi and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.6B | XXX | $1.6B | XXX | XXX | XXX |
| EV (current) | $1.6B | XXX | $1.6B | XXX | XXX | XXX |
| EV/Revenue | 5.0x | XXX | 5.2x | XXX | XXX | XXX |
| EV/EBITDA | 13.8x | XXX | 12.6x | XXX | XXX | XXX |
| EV/EBIT | 18.7x | XXX | 20.7x | XXX | XXX | XXX |
| EV/Gross Profit | 15.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | 18.3x | XXX | 17.6x | XXX | XXX | XXX |
| EV/FCF | 25.3x | XXX | 23.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialHammadi's last 12 month revenue growth is 11%
Hammadi's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Hammadi's rule of 40 is 49% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Hammadi's rule of X is 63% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Hammadi and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Margin | 36% | XXX | 41% | XXX | XXX | XXX |
| EBITDA Growth | 6% | XXX | -1% | XXX | XXX | XXX |
| Rule of 40 | 49% | XXX | 52% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 63% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 0% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 8% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Burjeel Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| PureHealth | XXX | XXX | XXX | XXX | XXX | XXX |
| Integral Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Ramsay Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Athens Medical Centre | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Hammadi acquired XXX companies to date.
Last acquisition by Hammadi was XXXXXXXX, XXXXX XXXXX XXXXXX . Hammadi acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Hammadi founded? | Hammadi was founded in 2004. |
| Where is Hammadi headquartered? | Hammadi is headquartered in Saudi Arabia. |
| Who is the CEO of Hammadi? | Hammadi's CEO is Mr. Mohammed Saleh Mohammed Hamad Al Hammadi. |
| Is Hammadi publicy listed? | Yes, Hammadi is a public company listed on SAU. |
| What is the stock symbol of Hammadi? | Hammadi trades under 4007 ticker. |
| When did Hammadi go public? | Hammadi went public in 2014. |
| Who are competitors of Hammadi? | Similar companies to Hammadi include e.g. Burjeel Holdings, PureHealth, Integral Diagnostics, Ramsay Health. |
| What is the current market cap of Hammadi? | Hammadi's current market cap is $1.6B |
| What is the current revenue of Hammadi? | Hammadi's last 12 months revenue is $320M. |
| What is the current revenue growth of Hammadi? | Hammadi revenue growth (NTM/LTM) is 11%. |
| What is the current EV/Revenue multiple of Hammadi? | Current revenue multiple of Hammadi is 5.0x. |
| Is Hammadi profitable? | Yes, Hammadi is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Hammadi? | Hammadi's last 12 months EBITDA is $116M. |
| What is Hammadi's EBITDA margin? | Hammadi's last 12 months EBITDA margin is 36%. |
| What is the current EV/EBITDA multiple of Hammadi? | Current EBITDA multiple of Hammadi is 13.8x. |
| What is the current FCF of Hammadi? | Hammadi's last 12 months FCF is $63.2M. |
| What is Hammadi's FCF margin? | Hammadi's last 12 months FCF margin is 20%. |
| What is the current EV/FCF multiple of Hammadi? | Current FCF multiple of Hammadi is 25.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
